Literature DB >> 6345804

Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein.

E E Walsh, J Hruska.   

Abstract

Six monoclonal antibodies directed against respiratory syncytial virus proteins were produced. Each was characterized by immunoprecipitation and indirect immunofluorescence. One was directed against the nucleocapsid protein. NP 44, two were directed against a 37,000-dalton protein, two were directed against the major envelope glycoprotein, GP 90, and one was directed against the 70,000-dalton envelope protein, VP 70. Indirect immunofluorescence stain patterns of infected HEp-2 cells defined GP 90 and VP 70 as viral proteins expressed on the cell surface, whereas NP 44 and the 37,000-dalton protein were detected as intracytoplasmic inclusions. One of the anti-GP 90 antibodies neutralized virus only in the presence of complement but did not inhibit cell-cell fusion. The anti-VP 70 antibody neutralized virus without complement and inhibited cell-cell fusion of previously infected HEp-2 cells, thus identifying VP 70 as the fusion protein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345804      PMCID: PMC255221     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Respiratory syncytial virus proteins.

Authors:  W H Wunner; C R Pringle
Journal:  Virology       Date:  1976-08       Impact factor: 3.616

3.  Respiratory syncytial virus polypeptides: their location in the virion.

Authors:  M Peeples; S Levine
Journal:  Virology       Date:  1979-05       Impact factor: 3.616

4.  Isolation of paramyxovirus glycoproteins. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein.

Authors:  A Scheid; L A Caliguiri; R W Compans; P W Choppin
Journal:  Virology       Date:  1972-12       Impact factor: 3.616

5.  Immunological studies of the functions of paramyxovirus glycoproteins.

Authors:  D C Merz; A Scheid; P W Choppin
Journal:  Virology       Date:  1981-02       Impact factor: 3.616

Review 6.  Production of monoclonal antibodies: strategy and tactics.

Authors:  S F de StGroth; D Scheidegger
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

Review 7.  The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses.

Authors:  P W Choppin; A Scheid
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

8.  The stabilization and purification of respiratory syncytial virus using MgSO4.

Authors:  B F Fernie; J L Gerin
Journal:  Virology       Date:  1980-10-15       Impact factor: 3.616

9.  Respiratory syncytial virus proteins: identification by immunoprecipitation.

Authors:  J M Bernstein; J F Hruska
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

10.  Antigen and polypeptide synthesis by temperature-sensitive mutants of respiratory syncytial virus.

Authors:  C R Pringle; P V Shirodaria; H B Gimenez; S Levine
Journal:  J Gen Virol       Date:  1981-05       Impact factor: 3.891

View more
  107 in total

1.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

3.  Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation.

Authors:  Lewis H McCurdy; Barney S Graham
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

5.  Distinguishing between respiratory syncytial virus subgroups by protein profile analysis.

Authors:  P Walpita; M A Mufson; R J Stanek; D Pfeifer; J D Connor
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

6.  Natural history of human respiratory syncytial virus inferred from phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide duplication.

Authors:  Alfonsina Trento; Mariana Viegas; Mónica Galiano; Cristina Videla; Guadalupe Carballal; Alicia S Mistchenko; José A Melero
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition.

Authors:  J P Matheise; K Walravens; A Collard; P Coppe; J J Letesson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants.

Authors:  P J Watt; M Zardis; P R Lambden
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.